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Abstract 
A growing body of scientific evidence has demonstrated that chronic psychological 
stress can not only increase the growth and metastasis of tumors through a number of 
mechanisms, such as by an increase of VEGF and Bcl-2, but also can decrease the 
survival of cancer patients. However, no studies have reported the effect of psychological 
stress with respect to the tumor marker MUC 1. Therefore, building upon previous 
research, the purpose of the present study was to investigate the effect of the stress 
hormones cortisol and norepinephrine on the tumor marker MUC1, which is highly 
associated with tumor cell metastasis and is aberrantly glycosylated in most human 
epithelial carcinomas. Thus, it has been widely used in clinics as an important prognostic 
marker of disease progression and response to treatment. Overexpression of MUel in 
prostate cancer has been associated with more aggressive disease and an increased risk of 
recurrence. 
Using the OU-145 prostate cancer cell line as an experimental model, we sought to 
determine whether the glucocorticoid cortisol and the catecholamine norepinephrine 
enhanced the expression of MUel at the transcriptional and protein levels, and whether 
increased MUCI altered the invasive potential of DV-145 cells. The levels of MUCl 
protein expression were assayed by ELISA, flow cytometry, and the colorimetric 
bradford assay. The mRNA levels ofMUCl were measured by RT-PCR. In addition, cell 
invasiveness and migration were assayed by the matrigel migration assay. 
The results indicate that physiologically relevant concentrations of cortisol found in 
tumor microenvironment (10 -7 M) enhanced the expression of MUCI by approximately 
2-fold after 6 or 10 days of treatment as assayed by ELISA. In addition, flow cytometric 
11 
analyses revealed that DU-145 cells treated for 3 or 6 days with cortisol up-regulated the 
cell-surface expression of Muel by approximately 2-fold, whereas a 10 day exposure 
up-regulated the expression by 7-fold. Norepinephrine alone did not alter the expression 
ofMUCl at any time point in any of the experiments. In addition to these elevated levels 
ofMUCl protein., the mRNA levels of MUCI were increased by 6-fold when cells were 
treated with cortisol for 6 days and by 4-fold when cells were treated for 10 days, while 
norepinephrine had no effect on mRNA levels. In addition, the matrigel migration assay 
indicated that cells treated with cortisol for 6-10 days migrated faster through the 
membrane as compared to untreated cells. 
Together, data generated from this thesis provide novel evidence of a biochemical link 
between the glucocorticoid cortisol, a hormonal mediator of psychological stress, and 
increased levels of the tumor marker MUC 1. Findings arising from this thesis raise the 
possibility that in prostate cancer the interaction of MUe 1 with stress hormones, such as 
cortisol may increase the expression of MUel resulting in the observed increase in 
disease in psychologically stressed individuals. These novel findings highlight the 
necessity for future studies designed to investigate further the relationship between 
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CHAPTER I 
INTRODUCTION TO THE RESEARCH 
1. Introduction to hormonal mediators of psychological stress, and the tumor marker, 
MUCI. 
1.1. Psychological Stress 
Despite extensive research on varIOUS aspects of stress, investigators still find it 
difficult to achieve a satisfactory definition of this concept (Segerstrom & Miller, 2004). 
We adopted the definition of stress based on two perspectives: psychological and 
biomedical. According to the National Cancer Institute (NCI), psychological stress refers 
to the ~~emotional and physiological reactions experienced when an individual confronts a 
situation in which the demands go beyond the person's coping resources". From the 
biomedical perspective, based on the pioneering work of Hans Selye (known as "the 
father of stress") and Walter Cannon (a pioneer in modem stress theory) (Mason., 1975)., 
stress is defined as "an alteration in the body"s honnonal and neuronal secretions caused 
by the central nervous system in response to a perceived threat" and a stressor is viewed 
as "a change in an individual~s internal or external enviromnent which is perceived by the 
organism as threatening" (Strange et al. 2000). In the~short term, stress promotes survival 
functions of the body by increasing blood pressure, blood sugar levels and promoting 
analgesia (Matousek et al. 2010). However, when stress persists over a long period of 
time (chronic stress) it is considered to be harmful and may promote a number of diseases 
(Kageyama, 2011; Habib et al. 2001; Chrousos & Gold, 1992). Chronis stress could last 
for days., months, or years (Antoni et al. 2006; Contrada & Baum., 2010). In acute stress., 
after the stress reaction is removed or ends the hormone levels start,to subside. In chronic 
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stress, however, the stress hormone production can be elevated for prolonged periods 
(Antoni et al. 2006). From the biochemical point of view, the survival of multicellular 
organisms depends on their ability to successfully adapt to their constantly changing 
environment. The nervous system and the endocrine system provide intracellular 
communication required for this adaptation (Murray et al. 2006). Therefore, excessive, 
deficient, or inappropriate production and release of hormones might lead to an 
imbalance of the required biological stability and in such way may contribute to the 
development of certain diseases. 
1.2. Neuroendocrine Responses to Psychological Stress: Glucocorticoids and 
Catecholamines 
There are two main neuroendocrine pathways activated in response to psychological 
stress: the hypothalamic-pituitary-adrenal axis (HP A) which when activated results in 
release of glucocorticoids (GCs), and the sympathetic nervous system, which results in 
the release of the catecholamines, epinephrine and norepinephrine (Marketon & Glaser, 
2008). In addition, there are other neuroendocrine factors released following stress such 
as growth hormone (GH) and nerve growth factor (NGF). See Figure 1. 
The hypothalamic-pituitary-adrenal axis (HP A) activation follows the release of 
corticotrophin releasing factor (CRF) and vasopressin which are produced in the 
hypothalamic paraventricular nucleus (PVN) of the hypothalamus (Webster & Glaser, 
2008). Consequently, these hormones stimulate the anterior pituitary to secrete 
adrenocorticotrophic hormone (ACTH) which is released into the blood and reaches the 
adrenal cortex, where it acts on the adrenal glands and causes the1jl to synthesize and 
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secrete glucocorticoids (Costanzo et al. 2011; Webster & Glaser, 2008). See Figure 2. 
These honnones regulate a wide variety of cellular processes via glucocorticoid receptor -
mediated activation or suppression of target genes. They interact with intracellular 
receptors, and fonn a ligand - receptor complex that directly provides the signal to 
specific genes whose rate of transcription is thereby altered (Webster & Glaser, 2008). 
Glucocorticoids act by binding to GC receptors which are followed by receptor 
translocation into the nucleus and trans-activation or trans - repression of target genes 
(Kino, 2007). They exert their effects through their ubiquitously distributed intracellular 
receptors. In the absence of ligand, the non-activated GCR resides in the cytoplasm of 
cells and act as part of a large multiprotein complex consisting of the receptor 
polypeptide, two molecules of hsp90, and several other proteins (Kino, 2007). Chaperon 
proteins keep the GCR in an inactive state. Upon hormone binding, the receptor 
dissociates from hsp90 and other proteins and translocates into the nucleus, where it 
binds as a homodimer to glucocorticoid-response elements (GREs) located in the 
promoter region of target genes, and regulates the expression of glucocorticoid-
responsive genes positively or negatively, depending on die GRE sequence and promoter 
context (Kino, 2007). See Figure 3. The receptor can also modulate gene expression 
independent of GRE-binding by physically interacting with other transcription factors 
such as AP-l and NF-kB; the latter protein is known to be up-regulated in inflammation 
and in nearly all tumors. It is important to note that glucocorticoid's effectiveness in 
target tissues is regulated by numerous factors at each step of the GCR signaling cascade 
(Kino, 2007). Glucocorticoids are synthesized in a final form and secreted immediately, 
'r. 
so there is no intracellular reservoir of these hormones (Murray et al. 2006). Basal 
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secretion of GCs is necessary for the nonnal function of many tissues. They are also 
necessary for maintaining the homeostasis of the eNS, the cardiovascular system, and 
metabolism. In addition, at ~ropharrnacologic" doses (10 -8 mallL) they are used as 
immunosuppressive and anti-inflammatory agents for many diseases (Kino, 2007). An 
excess of circulating glucocorticoids, which can occur as a result of chronic stress., is 
associated with increased susceptibility to viral infections, prolonged wound healing and 
decreased antibody production after vaccination (Sternberg et a1. 2006). Therefore, a fine 
balance of glucocorticoids is required for the maintenance of homeostasis. 
The second neuroendocrine pathway involves activation of the sympathetic nervous 
system resulting in the release of the catecholamines. Catecholamines [dopamine (DA)., 
levodopa (L-Dopa)., epinephrine (EP) and norepinephrine (NE)] playa significant role in 
the nervous system as central and peripheral neurotransmitters (Sanghavi et a1. 2012). 
They maintain notmal physical activity of the body including blood pressure, heart rate 
and the reactions of the sympathetic nervous system (Kumar et a1. 2011). In addition, 
very high levels of catecholamines in biological fluids may indicate neural and/or tumors 
of adrenal glands (Barron, 2010). Catecholamines are synthesized in a final fonn and 
stored in granules in the chromaffin cells of the adrenal medulla. In response to 
appropriate neural stimulation, these granules are released from the cell through 
exocytosis, and the catecholamines are released into the circulation. A reservoir supply of 
catecholamines exists in the chromaffin cells, which can be released over several hours 
(Murray et a1. 2006). Catecholamines initiate their biological effect by binding to 
receptors located in the plasma membranes of cells and generate a signal that regulates 
various intracellular functions. Catecholamines have hormone recognition and signal 
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generation domains. Catecholamines bind to the ~2 - adrenergic receptor and stimulate 
activation of a G-coupled protein resulting in increased intracellular cAMP (Marketon & 
Glaser, 2007). 
As described above, glucocorticoids and catecholamines possess different functional 
characteristics. See Figure 4. For example, cortisol is lipophilic, has transport proteins 
and mediates its effect via receptor hormone complex, whereas norepinephrine is 
hydrophilic, has no plasma transport proteins and mediates its effect via cAMP (Murray 
et aL 2006). These different characteristics suggest that cortisol and norepinephrine may 
act in a different manner with respect to the up-regulation of tumor markers. 
1.3. ·Cortisol- a Biomarker of Psychological Stress 
Cortisol is considered a validated biomarker for assessment of HP A axis function 
(Tornhage et al. 2009). Cortisol can be measured in urine., plasma and saliva. The latter is 
known to be a reliable measure of the unbound, biologically active cortisol in blood 
(Weinrib et aL 2010). In plasma, the majority of circulating cortisol is tightly bound to 
CBO (corticosteroid-binding globulin) and the rest to albumin. The remaining hormone is 
free or unbound and is thought to be available to exert other biological functions. Levels 
of cortisol found in saliva are significantly lower than those found in plasma (Matousek 
et aL 2010), since salivary cortisol is more closely correlated with the free fraction in 
serum than to total serum cortisol. Literature (Turner ~ Cobb et al. 2000; Sephton et al. 
2009) indicates that depressed individuals exhibit higher cortisol secretion rates and have 
flattening cortisol rhymes. In addition, some researchers report (Luecken & Compas, 
2002) that disrupted circadian rhythms of cortisol in cancer patients"'-can lead to an earlier 
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mortality as cortisol is capable of influencing neoplastic cell growth by altering cell 
adhesiveness, cell division, and metastatic potential (Luecken & Compas; 2002). In 
addition, some studies report that elevated levels of cortisol is positively correlated with 
the severity of the disease in breast cancer patients (Banu et al. 1988; Van der Pompe et 
al. 1996). 
1.4. MUC1- a Biomarker of Tumor Progression 
MUCl, also named DF3, episialin, CA 15-3, P AS-O, or polymorphic epithelial mucin 
antigen (PEM) (Schumacher & Adam, 1998) is encoded by the MUCI gene, located on 
chromosome lq21, and is expressed on the ductal cell surface of normal glandular 
epithelia originating from gastro-intestinal, respiratory and urinary tracts and in breast, 
ovary and testes (Papadimitriou-Taylor et aL 1998). MUC 1 is known to be over-
expressed by a diverse number of human carcinomas and some hematologic malignancies 
(Duraisamy et aL 2007). In malignant cells, MUCI is over expressed over the entire cell 
surface resulting in increased exposure to molecules found on other tissues or blood 
vessels, such as ICAM-l and shedding into the circulation;> (Duraisamy et al. 2007). This 
characteristic makes Muel a valuable tumor marker. In fact, more than 20 years ago 
MUCI was identified and validated as a tumor antigen. Since then it has widely been 
measured in clinics using FDA approved commercially available kits (CA 15-3), as an 
important prognostic marker to monitor patients' clinical treatment response, time to 
disease progression and survival (Park et a1. 2007). 
In summary, as mentioned above, chronic psychological stress leads to the excessive 
production and release of two main stress hormones: cortisol and norepinephrine which 
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mediate the response to stress VIa two different neuroendocrine . pathways: the 
hypothalamic-pituitary-adrenal axis (HP A) and the sympathetic nervous system. Thus, 
the glucocorticoid cortisol and the catecholamine norepinephrine are known to be the 
markers of psychological stress. In addition, MUel is considered a validated tumor 
marker which is associated with tumor cell metastasis and is aberrantly glycosylated and 
up - regulated in most human epithelial carcinomas. Therefore, focusing on two main 
physiological markers of psychological stress (cortisol and norepinephrine) and the tumor 





2.1. Stress and Cancer Progression 
There is a long history regarding the question of whether psychological factors can 
influence the etiology and progression of cancer. It has been known for a long time that 
chronic, stress affects a variety of processes within the body~ and has been linked with 
adverse health outcomes. More specifically, studies have shown that psychological stress 
heightens the risk of coronary artery disease (Rozanski et aL 1999), respitory infection 
(Cohen et a1. 1991), and produces changes in immunity (Rabin, 1999). In terms of cancer, 
the link between psychological stress and tumor initiation still remains unclear (Chen et 
aL 1995; Protheore et a1. 1999). However, the link between the effect of psychological 
stress and tumor progression is stronger (Chida et al. 2008; Antoni et al. 2006). 
Therefore, this literature review focuses on studies investigating the effect of stress on 
tumor growth and metastasis and omits studies investigating the effects of stress on the 
initiation of cancer. Thus~ this review refers to chronic psychological stress only which 
persists over an extensive period of time: days~ months., years. 
Stress and cancer have been known to be linked in many ways (Chida et al. 2008; 
Antoni et aL 2006). However, these connections became serious research targets just 
quite recently. The complexity of psychological stress itself and methodological 
limitations to measure stress are a few of the obstacles limiting our understanding of how 
stress and cancer are relatedw In general~ there are four key components in the design of 
studies investigating the relationship between psychological stress and cancer: tumor 
model, type of the stressor, timing of the stressor, and the frequ~ncy and duration of the 
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stressor (Contrada & Baum., 2010). To investigate the effect of psychological stress on 
tumor progression, researchers have used tissue culture, animal models and human 
clinical approaches. In terms of stressors, they could be divided into two main categories 
- physical and psychological. The first type refers to such stressors as heat, cold, surgery, 
involving an insult to the tissues of the organism, whereas the second type induces the 
anticipation of threat or harm (Strange et al. 2000). Also, there could be a psychosocial 
stressor which results from the responses to the social interactions or lack of such 
interactions (Strange et al. 2000). Animal model studies use the following types of 
stressors: 1) restraint (an animal placed in a confined space, preventing it from moving 
freely); 2) forced swimming (an animal placed in a cylinder of water); 3) and social 
isolation stress (where an animal is being isolated from others) (Kemeny & Schedlowski, 
2007). To measure psychological stress, researchers often focus on the following 
mediators of psychological stress: the glucocorticoid cortisol (CORT), the 
catecholamines norepinephrine (NE) and epinephrine (EPI), as well as the synthetic 
glucocorticoid dexamethasone (DEX) (Nillson et al. 2007; Shahzard et al. 2010; Imai et 
al. 2004). It is important to note that the doses of stress hortnones used in such studies are 
, 
selected to mimic the physiological levels of these hormones found at the site of the 
tumor in cancer patients. As outlined in the introduction, it has been documented (Sloan 
et al. 2010; Shimizu et al. 1994; Madden et al. 1995) that psychological stress evokes the 
release of micromolar concentrations of cortisol, norepinephrine, and epinephrine into the 
tumor microenvironment, but nanomolar concentrations into the systemic circulation. 
9 
Current studies use the following markers to investigate tumor progression: VEGF 
(Vascular endothelial growth factor) (Thaker et al. 2006), interleukins (Nillson et al. 
2007; Shahzard et a1. 2010), MMP (Matrix metalloproteinases)(Thaker et a1. 2006; Yang 
et al. 2006; Sood et at 2006; Landen et a1. 2007; Lutgendorf et a1. 2008), kinases (Thaker 
et al. 2006), and various transcription factors. All of them are known to be involved in 
cancer pathogenesis and therefore serve as good indicators of cancer growth and 
progression. More specifically, VEGF is a protein that stimulates vasculogenesis and 
angiogenesis, so high levels of this protein allows cancers to grow and metastasize 
(Thaker et aL 2006). Various interleukins, such as IL-6., are known to be elevated in 
cancer patients and thought to be associated with an increased tumor burden (Nillson et 
aL 2007). MMPs play a big role in tumor cell invasion and migration (Landen et al. 
2007). To the best of our knowledge, no studies attempted to investigate psychological 
stress effect on the tumor marker MUC 1. 
The data from animal models appears to demonstrate the most compelling evidence 
that psychological stress might affect cancer growth and progression. A number of 
studies (Nillson et al. 2007; Shahzard et a1. 2010) demonstrate that chronic stress is 
" 
associated with increased levels of pro-angiogenic cytokines - IL-8 and IL-6 in ovarian 
cancer cell lines (SKOV3, SKOV3.ipl., Hey-A8). More specifically, treatment of ovarian 
cancer cells with norepinephrine and epinephrine were shown to significantly enhance 
the expression of IL-8. This effect was mediated by the ADRB2 and the FBJ murine 
osteosarcoma viral oncogene homolog B also known as FOSB (in humans) or FosB (in 
other species (Shahzard et al. 2010). In addition, Nillson et al. (2007) demonstrated that 
""c_ 
norepinephrine increased the expression of IL-6. An elevated level of this cytokine is 
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known to be associated with a poorer prognosis in ovarian cancer patients (Plante et a1. 
1994; Tempfer et a1. 1997). Therefore, enhanced expression of IL-6 by one of the stress 
hormones - norepinephrine suggests the important role psychological stress may play on 
ovarian cancer progression. These studies identified f)-adrenergic receptor/Scr tyrosine 
kinase signaling as the mechanism known to be critical in ovarian cancer progression. 
Other studies (Thaker et a1. 2006, Yang et al. 2006; Sood et al. 2006; Landen et a1. 
2007; Lutgendorf et a1. 2008) show that stress honnones can markedly increase the 
expression ofVEGF, MMP9, and MMP2 in ovarian cancer cells, animal tumor models 
and ovarian cancer patients. Thaker et a1. (2006) identified B-adrenergic activation of the 
cAMP-PKA signaling pathway as the most important mechanism by which stress can 
enhance tumor angiogenesis and promote malignant cell gro\Vth. Landen et aL (2007) 
demonstrated that increasing doses of norepinephrine and epinephrine increased levels of 
the phosphorylated signal transducer and activator of transcription -3 (STAT3) factor in 
ovarian cancer cells. Activation of STAT3 is associated with oncogenesis (Calo et al. 
2003)4 
Using an orthotropic mouse model of breast cancer, Sldan et al. (2010) showed that 
restrained stress led to a 30-fold increase in the size of the primary tumor and an increase 
in metastasis to distant tissues including the lymph nodes and lung as measured by in vivo 
optical imaging to track metastasis using luciferase -tagged 66c14. They identified 13-
adrenergic signaling as the main mediator of this effect. More specifically, ~- adrenergic 
signaling increased the infiltration of CD 11 b F 4/80 macrophages into primary tumor 
parenchyma and hereby induced metastatic gene expression. These findings highlight the 
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importance of the activation of the sympathetic nervous system as a novel regulator of 
breast cancer metastasis. 
Using an orthotopic mouse model of human ovarian cancer, Ani! et al. (2010) have 
shown that restraint stress and the associated increase in norepinephrine and epinephrine 
protected cells from anoikis (cells entering apoptosis when separated from ECM) and 
promoted their growth by FAK (Focal Adhesion Kinase) pathway. FAK localizes to focal 
adhesions and mediates physical attachment of cells to the ECM. 
In addition to the numerous studies investigating the effect of chronic stress on 
cancer progression in the laboratory settings, there are also studies conducted with 
humans. Those studies include the assessment of such psychosocial variables as 
depression, chronic stress, and social support. Chronic psychological stress which persists 
over a long period of time can increase the risk of major depression. Therefore, 
depression could be considered as a consequence of chronic stress. For example, 
Lutgendorf et a1. (2008) showed that ovarian cancer patients with elevated levels of 
depressive symptoms and low social support showed elevations in MMP9, whereas 
patients with high social support and other psychosocial factors have lower levels of 
, 
VEGF and MMP9. It was also shown that higher levels of depression (CESD, scale > 16) 
were associated with a significant increase in F AK expression and a highly significant 
increase in phosphorylated F AK, a protein involved in cellular adhesion and spreading 
processes. 
These findings from the studies mentioned above indicate that the neuroendocrine 
system plays an important role in the tumor microenvironment and the facilitating of 
'". 
tumor growth. Specifically., stress hormones have been shown to be capable of altering 
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tumor growth by enhancing the levels of VEGF, various cytokines, MMPS, 
transcriptional factors. Together, these studies offer insight into the mechanisms of how 
chronic psychological stress may affect tumor progression. Indicatively, the J3-adrenergic 
pathway has been hypothesized to be a main mechanism mediating the stress effect on 
tumor growth and metastasis (Landen et aL 2007; Thaker et aL 2006, Yang et aL 2006; 
Sood et al. 2006). The majority of these studies use ovarian cancer as a model; therefore 
there is a need to explore this relationship with other cancers, especially in light of the 
positive results obtained from ovarian cancer studies. Also, many studies (Nilsson et al. 
2007; Landen et a1. 2007; Antoni et a1. 2006) suggest that the underlying mechanisms 
mediating this effect are still poorly understood and more research is needed. Therefore, 
by using cortisol and norepinephrine and looking at a different pathway, this thesis 
proposes a novel mechanism by which psychological stress might alter tumor growth and 
progression. In addition, since this thesis focuses on the effect of psychological stress 
and highlights the importance of psychological interventions., it is essential to note that 
there is disagreement within the field concerning the true impact of how psychological 
interventions affect patients' survival. A landmark study led by Spiegel et al. 1989 
:r 
showed an 18-month survival time advantage in women with metastatic breast cancer 
who had followed stress management and social support intervention. In addition, 
Grossarth et a1. (1989) reported a longer survival for breast cancer patients receiving 
individual psychotherapy. A significant survival advantage following participation in 
group psychotherapy interventions was also reported among malignant melanoma 
patients (Fawzy et a1. 1995). In contrast, several studies (Goodwin et al. 2001; Edelman 
'--
et aL 1999; Gellert et aL 1993) failed to demonstrate a significant effect of psychological 
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interventions on cancer progression and survival. In summary, due to mixed results on 
the survival outcomes, the true impact of psychological interventions on survival of 
cancer patients remains controversial, and more in depth studies addressing these issues 
are needed. 
2.2. MUel and Cancer 
The MUCI family of molecules consists of secreted (M'UC2, MUe3, MUC5AC., 
MUC5B, MUC6) and membrane bound fonus (MUel, MUe3, MUC4, MUC12, 
Mue 13, MUe 16, MUC 17) .. Both types of these mucins form a physical gel barrier that 
protects epithelial cells of specialized organs such as kidney; pancreas, and liver 
(Duraisamy et al. 2007). Among all identified mucins, MUel has been investigated most 
extensively (Li & Cozzi, 2007). 
MUCI is encoded by a single transcript and after translation undergoes autocleavage 
into two subunits (Kufe, 2009). The core protein of MUC 1 consists of the 20 amino-acid 
tandem repeat (TR) sequence "PDTRPAPGSTAPPAHGVTSA'\ an SEA domain, and a 
C tenninal cytoplasmic tail of72 amino acids (Pericleous et al. 2005). See Figures 5-6. 
if" 
The TR domain contains multiple 0 - glycosylation sites, with carbohydrate being the 
major portion of the mature mucin molecule (Walsh et aI., 2000; Papadimitriou et at 
1999)~ The major MUCI isoform is a type I transmembrane molecule with the mucin 
domain fonning a very large, rigid structure extending above the glycocalyx on the apical 
surface of epithelial cells. Several alternatively spliced isoforms have been described 
including a transmembrane isoform lacking the mucin domain and a secreted isofonn 
>.' ~ 
lacking the cytoplasmic and transmembrane domains (Walsh et ai. 2000). Up-regulated 
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expression of the major MUC 1 isoform is associated with gene amplification and/or 
increased transcriptional activation (Walsh et aL 2000). 
There are many murine antibodies produced which react with Muel (Taylor-
Papadimitriou et al. 1981). Most of them recognize exposed epitopes within the 20-mer 
tandem repeat region. The most commonly recognized epitope is the hydrophilic 
"PDTRP AP" sequence. The main antibody used in this thesis is a humanized IgG 1 k 
monoclonal human milk fat globule-l antibody (huHMFG 1) that was raised against the 
highly conserved and immunogenic core region of the extracellular domain of MUCI 
(Taylor-Papadimitriou et aL 1981). This monoclonal antibody (MAb) recognizes and 
binds with high specificity to the extracellular MUC 1 amino acid sequence, PDTR. 
Studies (Verhoeyen et al. 1993) revealed that huHMFG 1 binds to only those peptides that 
contain the PDTR sequence. This sequence is not exposed in normal epithelial cells, as it 
is fully glycosylated and masked by the carbohydrates. In epithelial cancers Muel is 
aberrantly glycosylated, leading to the exposure of this PDTR epitope; therefore, 
HuHMFGl has a high specificity to target a wide range of MUCI over expressing tumors 
and positively reacts with the human epithelial tumdr cell lines. It has been known 
(Mitchell et a1. 2002) that MUel expression is recognized by huHMFGl in many cancer 
cell lines which includes, but not limited to, the following: DU-145, MCF7, MB-231, and 
MB-453. 
Although MUel was initially identified as a tumor antigen, its gene is now known as 
an oncogene involved in both tumor formation and progression (Hattrup et al. 2006). 
MUCI can contribute to cancer pathogenesis via over expression caused either by the 
gene itself or by other genes involved in the modification of tm;" MUe 1 protein. Also, 
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Muel is believed to be involved In remodeling the tumor microenvironment by 
promoting tumor invasion, metastasis and growth (Walsh et aL 2000; Papadimitriou et aL 
1999). 
The ability of the MUCl to promote tumorigenesis and tumor progression originates 
from the interaction of its cytoplasmic tail (CT) with proteins involved in oncogenic 
signaling (Kufe, 2009). CT' contains mUltiple serine, threonine, and tyrosine residues, 
which are phosphorylated and involved in different signaling cascades. The CT can bind 
and signal through (3 - catenin and the mitogen - activated protein kinase (MAPK). In 
addition, CT interacts with members of the ErbB family, Wnt effector, EGFR and 
participates, in their downstream signaling pathways (Kufe, 2009). By binding to these 
other intracellular proteins MUel CT can migrate to the nucleus and regulate gene 
expression in such a way that MUCI becomes a highly specific tumor antigen (Taylor-
Papadimitriou et a1. 1981; Walsh et a1. 2000; Hattrup et a1. 2006; Kufe, 2006). These 
observations emphasize the importance of searching new signaling pathways that could 
affect MUCI regulation. 
Experimental manipulation of MUCI gene expression has indicated that MUCI IS 
capable of modifying in vitro adhesion and motifity, and is associated with increased 
metastatic behavior (Walsh et a1. 2000). MUCI glycosylation is frequently perturbed in 
malignant cells, with resultant truncated chains and the synthesis of sugar moieties not 
normally expressed .. 
The extracellular domain of MUC 1 has been shown to act as a ligand for the 
endothelial adhesion molecule (ICA~11), via sialylated carbohydrate structures known as 
selectins, which have domain homology with the ligand binding domain of cytokine 
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receptors (Ciborowski & Film; 2001). MUCI can interfere with integrins, receptors that 
mediate attachment between a cell and the tissues surrounding it, mediated adhesion to 
the extracellular matrix, and with cadherin mediated cell - cell adhesion, and can also 
enhance cellular motility. ECM proteins and their receptors are thought to play an 
important role in the initial stage of cancer cell attachment to the host tissue surfaces. It is 
documented (Ciborowski & Finn, 2001) that unlike normal cells in which the tandem 
repeat domain of MUClis 0- glycosylated at high density, tumor MUel contains 
multiple chains devoid of O-glycosylation and therefore these fragments of the 
polypeptide core of MUCI could be the candidates for interaction with matrix proteins 
and could promote attachment of tumor cells at distant sites. 
It has been known (Zaretsky et al. 2006) that Muel is predominantly hormonally 
regulated. More specifically, it is known to be transcriptionally regulated by estrogen, 
progesterone, and glucocorticoids. Although intensively studied, the mechanisms of 
steroid regulation of MUCI transcription remain unclear. It was reported (Zaretsky et al. 
2006) that estrogen increases MUCI expression. However, due to the different 
arrangements of cis-elements in the MUCI promoter this could lead to the competition of 
different transcription factors, the estrogen-altered expression might be cell and tissue 
specific (Zaretsky et aL 2006). Progesterone has also been shown to stimulate MUe 1 
expression (Wang et aL 2010). Glucocorticoid steroid response elements on the MUel 
gene were identified in the 1990s (Treon et al. 1999; Mitchell et al. 2002). However, in 
the following years, only a few studies have been conducted, to investigate the effects of 
steroids on Muel expression. 
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2.3. Glucocorticoids Expression on MUCI 
In the early 1990s several groups identified consensus sequences for estrogen, 
progesterone, and glucocorticoid steroid response elements on the MUCI promoter, 
suggesting that these steroids may up-regulate MUC1 transcriptionally. However, in the 
subsequent years only a few studies (Treon et at 1999; Mitchell et al. 2002) further 
explored the effects of steroids on MUC1 expression. The full length genomic sequence 
of MUC 1 (Lancaster et al. 1990) led to the identification of the glucocorticoid regulatory 
elements on the Muel promoter, including core a sequence (TGTTCT, TGTTCC) 
located on + 38 and 321, respectively and two consensus sequences 
(GCCTGAATCTGTTCT located on +29 and AGCTGGCTTTGTTCC located at -330). 
Glucocorticoid - dependent up-regulation ofMUCl has been documented in DU-14S 
cells previously. Treon et aL (1999) reported that dexamethasone (a synthetic 
glucocorticoid) induced MUCI expression in DU-14S as measured by flow cytometry 
and western blots .. More specifically, the highest induction of cell surface MUCI 
expression was seen using 10 ~8 mollL (a pharmacologically achievable dose) after 24 
hours treatment (Imai et a1. 2004). In DU-145 cells"" treatments with estrogen or 
progesterone receptor agonist or antagonist or alone with the glucocorticoid receptor 
antagonist RU486 did not alter Muel cell surface expression. Imai et al. (2004) showed 
that DU-145 cells treated with 10-8 M of dexamethasone expressed maximal levels of 
MUC1 after 6 days with an approximately 3-fold increase over MUC1 levels on non-
treated cells~ In addition., there was no significant difference in levels of MUel 
expression, between treatments with 10-8 and 10-5 M concentrations. After 15 days of 
dexamethasone treatment, DU-145 cells continued to express Muc'f at elevated levels. 
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These findings~ observed by other researchers (Imai et al. 2004; Treon et al. 1999), 
demonstrate that pharmacologica.lly achievable concentrations (10-8 to 10-5 M) of the 
synthetic glucocorticoid significantly up-regulated MUC1 expression in DU-145 cells 
and therefore give rise to the probability that these effects could be replicated using the 
glucocorticoid cortisol. 
Hypothesis 
As mentioned above, although a growing body of scientific evidence demonstrates 
that chronic psychological stress can affect tumor progression, the mechanisms that 
mediate this effect have not been completely defined. The best identified mechanism of 
how this may occur is via ~ - adrenergic signaling which was replicated by the J3 -
adrenergic agonist isoproterenol and stress responses were blocked by the J3 - blocker 
propranolol in mainly ovarian cancer models. Thus, to our knowledge, no previous 
studies have investigated the effect of psychological stress on biomarkers of tumor 
progression, such as MUC 1. Therefore, the investigation of relationship between cortisol 
and norepinephrine, as the main stress hormones, and MUC1, as a validated tumor 
marker, can contribute to narrowing the gap in understanding the mechanisms mediating 
psychological stress effect on tumor progression. 
Based on the relationship between psychological stress and tumor progreSSIon 
outlined above, this study tested the hypothesis that hormonal mediators of chronic 
psychological stress alter tumor progression by up-regulating the tumor antigen Muel in 
DU-145 prostate cancer cells. 
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More specifically., we hypothesized that the glucocorticoid cortisol and the catecholamine 
norepinephrine will up-regulate the expression ofMUCl in vitro. 
Specific Aims 
Specific Aim 1: To establish optimal stress honnone treatment parameters 
(dose, exposure times) for cortisol and norepinephrine. 
Specific Aim 2: To investigate the effect of cortisol and norepinephrine on MUC 1 
expreSSIon. 
Specific Aim 3: To investigate whether stress hormones can enhance the transcription of 
MUCl in DU-145 cells. 
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CHAPTER III 
MATERIALS & METHODS 
Cancer Cell Lines and Culture Conditions 
Human breast adenocarcinoma cell lines MDA-MB-231 (MB-231), MCF7, MDA-
MB-453 (MB-453), and prostate cancer cell line DU-14S were obtained from Dr. 
Fernandes of the Department of Biochemistry and Molecular Biology, Medical 
University of South Carolina. Cells were maintained and propagated in vitro by serial 
passage in RPMI 1640 medium (Invitrogen, # 10040CM) supplemented with 10% fetal 
bovine serum (FBS) and penicillin - streptomycin (lOOU/mL) (Gibeo, # 15140-122). 
Cultures were grown at 37°C in a 5% C02 humidified atmosphere and the experiments 
were performed with 70 - 900/0 confluent cultures. 
Reagents 
Hydrocortisone (cortisol) and norepinephrine were obtained from Sigma-Aldrich (Cat 
# H6909) reconstituted and stored at - 20°C. The humanized IgG 1 - type MUC 1 
monoclonal antibody, huHMFGl" and its recombinant GST-MUC1 antigen were 
provided by the biotech company, Antisoma Research Ltd, London, U.K. 
Concentrations of Stress Hormones 
The doses of stress hormones were selected to reflect physiological concentrations of 
these hormones at both the circulating level (0.003 - 0.006 JlM) and the level of the 
tumor microenvironment (0.1 - 1 J.lM). Prior to each experiment, stock hormones were 
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diluted in RPMI 1640 medium and exposed to cells within 5 min of preparation to 
minimize spontaneous degradation. 
Monoclonal antibody huHMFG 1 Concentrations 
HuHMFG 1 concentrations needed for measuring MUe 1 expression in each cancer 
cell line were determined by Enzyme-linked Immunosorbent Assay (ELISA) doing 
doubling dilutions of the antibody with the optimal concentrations generated from the 
standard curves using Sigma Plot 11.0. See Figure 7. 
Salivary Cortisol 
Saliva was obtained from healthy volunteers and salivary cortisol was measured in 
triplicate using Salimetrics kit (Cat # 1-3002) following the manufacture's protocoL 
Saliva samples were collected into the Salimetrics oral swabs and were stored at - 20°C 
or processed following the manufacture's protocol. Salivary cortisol concentrations were 
determined using a 4-parameter sigmoid minus curve fit (Aardal & Holm, 1995). 
Antigen Enzyme-linked Immunosorbent Assay (ELISA) 
Microtitre plates (96-well) were coated with GST-MUCI in 0.1 M sodium carbonate 
and incubated overnight at 4°C. The next day, the wells were blocked with PBS-Tween 
containing BSA (1 %) and incubated for one hour at 37°e prior to the addition of 
huHMFG 1 that was serially diluted using PBS. Antibody binding was detected using goat 
anti-human peroxidase conjugate IgG (Santa Cruz~ # SC-2453). Each incubation step was 
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followed by three PBS-Tween washes. The ELISA plate was developed with TMB 
substrate (Dako, # S 1599) and absorbance at 630 run measured. 
Cell Enzyme-linked Immunosorbent Assay (ELISA) 
Tumor cells (1 X I05cells/ml) were seeded in triplicate into wells ofa 96-well cell 
culture plate and incubated overnight at 37°C. The next day, the cells were fixed by 
replacing the medium with 4% fonnaldehyde in IX PBS and incubated for 15 min at 
room temperature. Triplicate wells in each treatment group were left without fixation for 
cell counting .. Formaldehyde was removed by aspiration with a pipette. The plate was 
washed by pipetting [(3X 300 fll) of PBS + Tween 20 (0.05%)] into each well., and the 
liquid was discarded by inverting the plate. After each wash, the plate was thoroughly 
blotted on paper towels before being turned upright. Following the addition of 100 fll of 
incubation buffer (PBS +Tween 20 (0.05%) + 3 % (w/v) BSA) into each well the plate 
was incubated for 1hr at 37°C. Appropriate concentration ofhuHMFGl was added and 
the plate incubated for 1.5 hour at 37°C. For detection, 100 f.ll of peroxidase conjugated 
goat anti-human IgG was diluted 1 :2000 in wash buffer/'and the plate was incubated for 
one hour at 37°C. The ELISA colorimetric assay was developed using 100 ~l of the 
TMB substrate added into each well and the plate was read at 630 every 5 min until 
maximum absorbance was measured. 
In order to control for any variations in cell number among the wel1s~ additional wells 
were not subjected to fixation but were trypsinized by adding 40 JlI of Trypsin/EDT A 
(0.05%) into each well and incubated at 37°C for 5 min. Then the plate was placed on the 
shaker for 8 min followed by addition of 80 Jll of RPM! 1640 tissue culture medium. 
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Cells were counted using a hemacytometer. Final absorbance was calculated by taking 
the optical density value with subtracted background and dividing it by the cell number 
count in each treatment group. 
The Bradford Colorimetric Assay (DCA) 
Protein standards were prepared using bovine serum albumin (BSA) (Thermo 
Scientific, # 23210) according to the manufacture's protocol. The reagent blank 
containing only PBS and Coomassie Plus Reagent (Pierce~ # 23236). A standard curve 
was generated by plotting the average blank-corrected 595 run measurement for each 
standard versus its concentration in J.1g/ml ofBSA. To measure total cellular MUCI 
protein, non - fixed cells from the cell ELISA assays were sonicated in PBS three times 
for 10 seconds each in a VirSonic sonicator (VirTis., Gardiner). After adding Coomassie 
Plus Reagent to all of the sonicated experimental samples, the absorbance values of the 
samples and reagent blanks were measured at 595 run following 10 min incubation at 
room temperature. Each sample was assayed in triplicate. The average absorbance at 
595 run for the reagent blank was subtracted from the absotbance at 595 om of the 
experimental samples. The protein concentration of the samples was then determined by 
comparison of the net absorbance of the samples to the absorbance values of the BSA 
standard curve. 
Flow Cytometric Analysis 
Cell surface expression ofMUCl on DU-145 cells was examined and quantified by 
flow cytometry. Cells were harvested from 75 cm2 flasks by washing wIth sterile PBS and 
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dissociation with Trypsin/EDTA (0.05%). Cells were washed twice with ice-cold PBS 
and 106 cells were resuspended in IX PBS containing 10 - 20llg/ml of huHMFG 1 for 2 
hours at 4°C in a volume of 1 ml. Goat anti-human IgG -PE (Santa Cruz, # SC-3736) 
secondary antibody was then added and incubated for 1 hour at 4°C in the dark. Each 
antibody incubation step was followed by centrifugation (5 min, speed 4) and 
resuspension of cells in 1 ml cold PBS. Flow cytometry data were analyzed with 
CellQuest™ from Becton Dickinson. 
RNA Isolation and Reverse Transcription peR 
Total cellular RNA was isolated from treated and untreated cells using Trizol reagent 
(Invitrogen, # 15596-026) following the manufacturer~s instructions. The RNA was 
quantified by spectrophotometry at 260 and 280 nm. Equal amounts of total RNA (5J..lg) 
from each sample were reverse transcribed using a High-Capacity eDNA Reverse 
Transcription Kit (Applied Biosystems, # 4368814). The resulting cDNA was amplified 
by PCR using primer pairs for the MUel (forward 5 '-
GGTACCTCCTCTCACCTCCTCCAA-3~; reverse 5' -," 
CGTCGTGGACATTGATGGTACC-3') and the GAPDH (forward 5'-
TGCACCACCAACTGCTTAGC-3"; reverse' -GGCATGGACTGTGGTCATGAG-3 '). 
MUCI primers were obtained from Fisher Scientific. GAPDH primers were provided by 
Dr. Spicer, Department of Biochemistry and Molecular Biology, MUSe. PCR was 
carried out for 35 cycles at 94°C for 30s, at 60°C for 1 min and 72 DC for 1 min. 




visualized under ultraviolet illumination. Product formation was quantified by 
determining the integrated density value of each band. 
Real Time -peR 
Real-time CRT-peR) was perfonned in triplicate and included GAPDH as a reference 
gene. For the 25-lll reactions, eDNA (2 tJ,1) was mixed with 12.5 1-11 of Maxima SYBR 
Green/Fluorescein q peR Master Mix (2X) (Fermentas, # K0241), 3 J.ll of forward 
primer, 3 J..11 of reverse primer, and 4.5 f.11 of nuclease-free water. Amplification was 
perfonned on Bio-Rad Thennal cycler at 50°C for 2 min and 95 °C for 10 min, followed 
by 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. Data were analyzed 
with automatic baseline and threshold settings for cycle threshold (Ct) determination. The 
levels of expression ofMUCl mRNA in each sample were normalized to the GAPDH 
mRNA levels. The final relative expression ofmRNA species was calculated using 2-delta 
Ct method. 
Matrigel Migration Assay 
The membrane invasion culture system chamber was used to measure the in vitro 
invasiveness of the DU-145 cells. Cells were incubated with 0.1 JlM of cortisol and 
norepinephrine for 1,3, or 10 days. Matrigel (Becton-Dixon, # 356230) was thawed 
overnight at 4°C. Plates and pipettes were chilled at -20°C. The matrigel was then diluted 
to 2 mg/ml in serum free-cold RPMI 1640 culture medium and 100 J.!l of the diluted 
matrigel was placed into the upper chamber of a 24-well transwell plate (Becton-Dixon, # 
35478). The plate was incubated at 37°C for 4 -5 hours to allow gelling. Cells were 
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harvested from tissue flasks by TrypsinlED'T A, washed three times with RPMI 1640 
containing 1 % FBS and then resuspended in RPMI 1460 containing 1 % FBS at a density 
of 106 cells/mL The lower chamber of the transwell was filled with 600 1-11 of culture 
medium containing 5 fJ.g/ml fibronectin as an adhesive substrate. The matrigel was gently 
washed with serum free culture medium. 100 III of cell suspension was placed onto the 
matrigel and the plate was incubated at 37°C for 20-24 hours. After the incubation, 
transwells were removed" fixed with 4% parafonnaldehyde and stained with a crystal 
violet. Noninvasive cells were scraped off the upper chamber of the transwell with a 
cotton swab and the cells were counted under a light microscope. To validate cells 
quantification, pictures of invaded cells were taken using Q Capture Pro software. All 
assays were done in triplicate and repeated once. 
In Vitro Scratch Assay 
Prior to conducting this assay, DU-14S cells were grown in T25 flasks and were pre-
treated for 3 and 6 days with 0.1 JlM of cortisol, norepinephrine, and both stress 
honnones, then cells were plated into 6 -well plates to create a confluent monolayer and 
incubated for approximately 24-48 hours at 37°C allowing cells to adhere and spread. 
Upon reaching confluency, the cell monolayer in each well was scraped with a p200 pipet 
tip in a straight line to create a "scratch". Scratches were made of approximately similar 
size in the assessed cells and control cells to minimize any possible variation caused by 
the difference in the width of the scratches. The debris was removed by washing the cells 
once with 1 ml of PBS and then fresh RMPI 1640 medium was added into each well. 
"'--
Cells were placed in the incubator at 37°C for approximately 24 hrS. After the incubation, 
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cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min and stained for 
15 min with crystal violet. Photographs were taken using Q Capture Pro software and by 
choosing the same reference point for each treatment condition. Five images were 
obtained for each well focusing on all directions of the scratch. 
Cell Growth 
DU -145 cells were seeded at 2 x 104 cells/ml in separate tissue culture dishes (Falcon, 
# 353004) containing standard culture medium (RPMI 1640) supplemented with 10% 
fetal bovine serum. This time point was considered day O. Following 24-48-72-96h 
incubation at 37°C with 50/0 CO2• Growth studies were performed in triplicate, where 
three separate measurements were obtained per day. Growth was determined by cell 
counts after day 0, at 24-48-96 hour intervals~ by using a Beckman Coulter counter. 
Results denote the average of triplicate measurements repeated three separate times. 
Statistical analysis compares the absolute numbers between groups at corresponding time 
points. Population doublings were calculated during the logarithmic growth phase by 
using Prism 4.03 GraphPad software. 
Statistical Analysis 
Statistical analyses were perfonned using SPSS.16 software. Statistical differences 
between the groups (untreated and treated cells) were assessed either using student t-test 




Specific Aim 1: To establish stress hormone treatment parameters: concentration 
and exposure times. 
A. Validating huHMFGl Binding in Different Cancer Cell Lines. 
To verify that each cel1line expressed MUel, the binding capacity of HuHMFGl to 
each cell line (DU-145, MCF7, MDA-MB-231, and MDA-MB-453) was determined by 
ELISA. Binding curves were fitted to a sigmoidal 4-logistic equation (Sigma Plot) and 
huHMFGI concentration was determined by looking at the saturation levels. These assays 
revealed that the highest binding capacity was observed in the DU-14S cell line which 
was selected as the main cell line to be used in our work for this thesis. See Figure 7. 
B. Determination of Stress Hormone Concentrations. 
Since there are no studies conducted to our knowledge on uSing stress hormones 
concentrations with respect to the tumor antigen MUel, the first sets of experiments 
were aimed at determining the concentrations of cortisol and norepinephrine to be used in 
following experiments. Our initial intention was to use just one stress honnone - cortisol. 
However, some studies (Antoni et aL 2006) have s'uggested that during acute stress, not 
only cortisol, but also norepinephrine is released., and that these two hormones may act in 
a synergistic or additive manner which in turn could lead to even greater impact on 
cancer related processes. Therefore, later in this project, we added norepinephrine as an 
additional stress honnone in our experiments. Thus, the rationale to add another stress 
honnone was based on the observed effects of norepinephrine on ovanan cancer 
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progression, such as enhanced expression of VEGF, MMP2, and MMP9 (Thaker et al. 
2006). 
It is well established that salivary cortisol is found to be a reliable surrogate for 
measuring circulating cortisol, so initially we aimed to mimic the physiological 
concentrations of salivary cortisol found in healthy stressed individuals. Previous studies 
(Turner - Cobb et al. 2000; Sephton et al. 2000) showed that the circulating level of this 
hormone in saliva is around 3-6 nM in healthy humans and is higher in distressed 
individuals. Additional experiments conducted with human saliva samples confirmed that 
healthy subjects' salivary cortisol level is around 0.003 J.!M. Based on this reasoning., we 
increased the nonnal salivary cortisol level found in humans by several fold, and used the 
following concentrations for in vitro experiments (J..lM): 0.0033, 0.0066, 0.0132, 0.025, 
0.05, 0.075. Experiments conducted using these cortisol concentrations did not show any 
significant enhancement of MUC1 expression. See Figures 9-11. However, it was 
reported that psychological stress evokes the release of micromolar concentrations of 
cortisol and norepinephrine into the local tumor microenvironment, but nanomolar 
concentrations into the systemic circulation (Sloan et at. 2010; Shimizu et al. 1994; 
Madden et al. 1995). This phenomenon could be explained by the hypervascularisation 
of the tumor environment, which compared to normal tissue requires significantly higher 
concentration of hormones and gro\Vth factors than those found in the peripheral 
circulation (Flint et. al. 2009). Since this study was designed to look at disease 
progression and not the onset of the disease, we estimated the experimental stress 
hormone concentrations to be around 0.1 ~M - 1 J.lM, which mimic the physiological 
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levels of circulating cortisol and norepinephrine generated during acute stress in the 
tumor microenvironment (Flint et al. 2009). 
c. Determination of Stress Hormones Exposure Times. 
A lack of evidence on investigating the effect of cortisol and norepinephrine on the 
expression of Mue 1 led us to experiment with a broad range of exposure times ranging 
from 1 day to 58 days. Based on very few studies (Imai et a1. 2004) showing MUCI 
enhancement in DU-145 prostate cancer cells after treating them with dexamethasone 
(synthetic glucocorticoid) for 3 to 15 days treatment, all our experiments were conducted 
with cells treated with stress hormones for 3, 6 and 10 days. 
D. Preliminary Experiments Investigating MUCI Expression in Various Cancer 
Cell Lines: MCF7, MDA-MB-231, and MDA-MB-453 Cells Using Cell Based ELISA 
Assay. 
Initially, prior to choosing the DU-145 cancer cell line as the main experimental 
model to test our hypothesis, other cancer cell lines (MOP?, MDA-MB-231, and MDA-
MB-4S3) were also tested for MUC1 expression. The choice to use breast and prostate 
cancer cell lines were based on the fact that these two types of cancer are honnonally 
driven. Early experiments were designed to obtain preliminary data on determining which 
stress honnone concentrations to use. 
Varying concentrations of cortisol (0.003 - 0.0132 J.lM), there was a decrease seen of 
MUC 1 expression in MCF? cells. Norepinehrine (0.1 JlM) alone slightly, but not 
significantly, increased the expression ofMUC1 on MCF? cells. See'" Figure 9. 
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Using concentrations of cortisol (0.025 - 0.5 JlM) on MDA-MB-231 cells, there was a 
lack of a consistent pattern of MUC1 expression. Apart from treating cells with 0.1 J,lM, 
all other concentrations either had no effect or had a down - regulation effect on MUCI 
expression. See Figure 10. MDA-MB-453 cells treated for 2 and 10 days with 
norepinehrine (0.1 flM) alone had a slight increase in MUCI expression. See Figure 11. 
Later preliminary experiments included DU-145 cells treated with stress honnones for 
3 and 58 days. See Figure 12. After seeing a significant increase in MUCI expression, 
these experiments gave rise to the use of the DU-14S prostate cancer cel1line as the main 
in vitro model for testing our hypothesis. 
In summary, preliminary experiments conducted with different cancer cell lines and 
different stress hormone concentrations and exposure times helped to detennine which 
cancer cell line to use and for how long to treat cells with cortisol and norepinephrine . 
As a result of these experiments, we decided to choose DU-145 prostate cancer cell line 
and to treat these cells with 0.1 f.lM of cortisol and norepinephrine. 
Specific Aim 2: To investigate the effect of stress hormones on MUCI expression. 
A. Alteration of Cell Growth in DU-145 Cells by CORT and NE. 
Cell growth experiments revealed that DU-145 cells treated with cortisol and 
norepinephrine grow faster than un-treated cells. See Figure 8. This suggests that treated 
cells may have a higher proliferative capacity as compared to untreated cells. 
Significantly increased growth of treated cells was observed after 4 days (* P< 0.001) 
compared with untreated cells using t-test analysis. 
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B. Investigating MUCI Expression in DU-14S Cells Using Cell Based ELISA Assay. 
To examine the effect of stress honnones on MUCI expression in DU-145 cells, the 
cells were stimulated with physiologically relevant concentrations (0.1 JlM) of cortisol 
and norepinephrine for 3,6, and 10 days and assayed for MUCI expression by cell based 
ELISA. In an attempt to be certain that the measured absorbance (00 630) was not 
influenced by possible differences in cell number between the experimental groups, cells 
were counted in each treatment group prior to fixing them. Results are presented in two 
formats: absorbance values not adjusted for the cell number and absorbance values 
adjusted for the cell number. Since one day prior to the experiment cells were harvested, 
transferred into 96-well plates, and left overnight to attach, the cells did not have much 
time to grow. Therefore, we did not expect to see a significant difference in the number 
of cells between treated and un-treated cells. Data generated from at least two 
independent experiments for each time point revealed the same pattern of an increased 
MUCI expression in cells treated with cortisol alone. See Figures 13-15.This increase 
became statistically significant after 10 days of treatment. In terms of the extent of 
increased expression, an approximately 1.S-fold increase:in expression was seen after all 
exposure times in cells treated with cortisol. Norepinephrine alone did not have any effect 
on MUCI expression at any time point. In conclusion, 6-10 days stimulation of DU-14S 
cells with cortisol alone noticeably enhanced MUClexpression. Although data suggest 
that cells treated with both stress hormones for 10 days had a significant increase in 
MUCI expression, however since norepinephrine alone did not have any effect, this 
increase was likely caused by cortisol alone. 
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c. Cell Surface Expression of MUCl Assayed by Flow Cytometry. 
After observing the effect of stress hormones on MUCI expression, as measured by 
ELISA, we further sought to investigate this increased expression by using flow 
cytometry, hence testing for similar effects by two orthogonal methods. Results are 
presented as mean fluorescence intensity of the hormone treated cells normalized to the 
mean fluorescence intensity of the untreated control cells. Flow cytometric analyses taken 
from two independent experiments performed with untreated and treated (3, 6, 10 days) 
DU-145 cells revealed a significant (p> 0.05) up-regulation of MUCI by cortisol alone 
during all exposure times. See Figures 16-19. More specifically, 3 and 6 day exposure to 
cortisol alone resulted in a 2-fold up-regulation ofMUCl. In addition, a 10 day exposure 
to stress hormones resulted in continuous up-regulation with a 7-fold increase when cells 
were treated with cortisol alone. Norepinephrine alone did not have any effect on MUC1 
expression levels., irrespective of the incubation time. Therefore when cells were treated 
with both stress hormones and resulted in a significant increase in MUCI expression, this 
effect was caused by the cortisol alone as was observed by the ELISA assay. 
In summary, flow cytometry experiments show that cortisol alone can significantly 
up-regulate MUel cell surface expression in DV-14S cells. Since it is well accepted 
(Snijdewint et a1. 2001) that in malignancy MUCI loses its polarized expression and is 
expressed on the whole cell surface, this finding indicates that cortisol may increase the 
cell surface expression of MUC 1 which could lead to tumor progression and metastasis. 
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D. Measuring MUCI Levels Expressed as a Function of Total Cellular Protein by 
the Bradford Colorimetric Assay (BCA). 
To further examine whether the exposure to stress hormones leads to an increase in 
MUCl protein levels, DU-145 cells were treated with cortisol and norepinephrine for 3, 
6, or 10 days and total protein amounts were assayed by the BCA assay. This assay alone 
measures just the total protein amounts, and it does not measure specifically the levels of 
MUCl protein. Therefore, in order to nonnalize MUel protein levels to the total cellular 
protein level, the total absorbance obtained from the ELISA assay was divided by the 
total protein amount obtained from the BeA assay. In this way the Muel levels were 
normalized to the protein level. See Figures 20-22. 
Data generated from three different exposure times revealed that treatment with stress 
hormones led to the increase in MUel protein levels at each time point. After adjusting 
for the cell number, the amount of MUClprotein in cells treated with cortisol alone was 
approximately 2-fold higher as compared to untreated cells at each time point. See 
Figures 20-22. In summary, treatment with cortisol alone appears to increase the 
MUClprotein levels in DU-l4S cells at each time point.''< 
E. Assessing Migration and Invasion of DU-145 cells. 
The effect of stress hormones on DU-145 cells invasion and migration was assessed 
by the matrigel migration assay. The matrigel matrix serves as a reconstituted membrane 
in vitro and blocks non - invasive cells from migrating through the membrane. Therefore, 
cells migrating through the membrane are considered to have increased invasive 
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properties. Cells were pre-treated with 0.1 J-lM of cortisol., norepinephrine., or both stress 
honnones for 3., 6., or 10 days and then tested for migration efficiency twice. 
Results are presented as the average number of invasive cells/field. Data show that 
norepinehrine alone did not influence migration of DU-145 cells at any time point. 
Treatment with cortisol consistently increased the migration by approximately 1.4- fold. 
Interestingly., the combination of both stress honnones led to the highest migration 
(increased by 3 -fold) after treating the cells for 6 days. See Figures 23-25. 
In summary, the matrigel migration assay results show that treating DU-145 cells with 
cortisol may increase the invasive potential of prostate cancer cells, possibly allowing 
them to invade into the extracellular matrix which is a critical requirement for tumor cell 
metastasis. Unexpectedly, data indicate that cortisol and norepinephrine acted in a 
synergistic manner by increasing DU-145 cells migration after the cells were treated with 
both stress hormones for 6 days (see Discussion). 
Specific Aim 3: To investigate whether stress hormones can enhance the 
transcription of MUCI in DU-145 cells. 
A. Measuring MUCl mRNA levels. 
To further define the mechanisms by which stress hormones regulate MUCI 
expression in DU-145 cells, we examined whether the up-regulation of expression of 
MUC 1 was a result of stress honnone- dependent transcriptional regulation. DU -145 cells 
were cultured in the presence of 0.1 J-lM cortisol., norepinephrine and both stress 
honnones for 3, 6, or 10 days, and MUCI mRNA levels were measured by RT - peR. 
'",' 
This concentration of hormones was used because it resulted in the most robust effect in 
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previous experiments. All experiments were done twice. Results are expressed In 
normalized fold expression compared to the house keeping gene - GAPDH. 
Three days treatment of DU-145 cells with cortisol or norepinephrine alone or in 
combination did not show any alteration of MUCI mRNA levels. More specifically., the 
normalized fold expression for the above mentioned treatment groups were as follows: 
cortisol alone (1.2 - fold), norepinephrine alone (0.5 - fold), and both (O.9-fold). See 
Figure 26. However, 6 day stress honnone treatment produced up-regulation of MUCI 
mRNA levels, with a 6 - fold increase in cells treated with cortisol., a 2 -fold increase in 
cells treated with norepinephrine and a 3.6-fold increase in cells treated with both stress 
hormones. See Figure 27. Continuous exposure (10 days) to stress hormones up-
regulated Muel mRNA levels in DU-145 cells treated with cortisol (with a maximum of 
3.5 - fold increase). See Figure 28. Norepinephrine alone did not have any effect on 
mRNA levels ofMUCl. 
These results indicate that 0.1 11M of cortisol alone alters Mue 1 mRNA levels after 6 
and 10 days treatment. Interestingly, the combination of cortisol with norepinephrine had 
a smaller effect on mRNA levels than cortisol alone. Further experiments should be 
designed in order to investigate the possible mechanisms accounting for the increased 




There are two maIn systems activated within the human body during chronic 
psychological stress: the sympathetic nervous system and the pituitary adrenal axis. They 
mediate the response to stress by the release of glucocorticoids and catecholamines. The 
data outlined in the literature review indicate that these hormonal mediators of stress can 
contribute to cancer growth and progression. However, as of today, there is a lack of 
evidence delineating the biological mechanisms involved. Using an in vitro system, this 
thesis represents a novel study of biochemical links between psychological stress 
hormones and Mue1 antigen expression. Building upon previous research, we 
hypothesized that the glucorticoid cortisol and the cathecolamine norepinephrine will up-
regulate the expression of the tumor marker MUe 1. 
Data arising from the three specific aims show that treating DU-145 prostate cancer 
cells with physiologically relevant concentrations (0.1 JlM) of cortisol results in 1) 
alteration of DU-14S cell growth; 2) enhancement of MUC1 expression; 3) alteration of 
.. 
DU-145 cells invasive potential; and 4) an increase in MUC1 mRNA levels. In contrast, 
the catecholamine norepinephrine does not have any notable effect on Mue1 expression. 
See Figure 30. Based on initial experiments conducted with different cancer cell lines 
and different stress hormones concentrations, MUel expression was found to be cancer 
cell line specific and to depend on the stress honnones concentration used as well as on 
the exposure times. For example, cortisol (0.1 J..lM) had a down-regulation effect of 
MUCl expression on MCF7 cells, but up-regulation effect on DU-145 cells. Also, the 
"",,,. 
longer the cells were exposed to cortisol, the higher decrease of-MUC1 expression was 
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observed in MCF7 cells. See Figures 9-12. Based on ELISA assay, 10 days stimulation 
of DU-l45 cells with cortisol alone significantly enhanced Muel expression. 
Furthermore, flow cytometric analyses revealed a significant up-regulation of MUel by 
cortisol during all exposure times. In addition, data arising from the combined analysis of 
Muel expression obtained from ELISA and the BeA assay revealed that pre-treatment 
of DU-145 cells with cortisol for 3, 6, or 10 days resulted in approximately 2-fold 
increase in MUCI protein levels as compared to un-treated cells at each time point. The 
data from the matrigel assay suggest that treating DU-14S cells with cortisol for 3 - 10 
days may increase the invasive potential of prostate cancer cells. Finally, RT - peR 
results indicate that the concentration of 0.1 ~M of cortisol alters Muel mRNA levels 
after 6 and 10 days treatment, and therefore the up-regulation of MUC 1 might be the 
result of increased transcription or increased mRNA stability. 
It is important to note that although it may seem that there is a consistent pattern 
indicating that cells treated with cortisol in combination with norepinephrine have a 
higher MUCI expression as compared to un-treated cells throughout all the experiments. 
However, data show that norepinephrine alone does '<-not have any effect on MUCI 
expression and therefore although it seems that cells treated with both stress honnones 
have higher expression of MUC 1 as compared to un-treated cells, this effect is caused by 
the cortisol alone. 
This study using in vitro model investigates psychological stress effect on tumor 
progression with a greater experimental control and validity as compared to other 
experimental models regarding the identification of mediating processes involved. More 
'"' ~ 
specifically, we propose the following pathway as a potential mechanism by which stress 
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hormone cortisol can up-regulate MUCl expression: first., chronic psychological stress 
leads to the release of cortisol which binds to the glucocorticoid receptor and then 
associates with hsp90. Second., it dissociates from hsp90 and translocates into nucleus 
where it binds as a homodimer to GREs located in the promoter region of MUCI and 
from there it regulates the expression of MUe 1. 
In conclusion., this study combined with other reports discussed in this thesis, explores 
two neuroendocrine pathways as potential mechanisms mediating the effect of chronic 
psychological stress on tumor progression. More specifically, the hypothalamic-pituitary-
adrenal axis (HPA) which results in release of glucocorticoids (GCs) was found to 
influence MUCI expression in DU-145 prostate cancer cells. In contrast, another 
neuroendocrine pathway, involving the sympathetic nervous system, which results in the 
release of the catecholamines, epinephrine and norepinephrine, was not found to 
influence MUe1 expression in DU-145 prostate cancer cells. Since we hypothesized that 
both the glucocorticoid cortisol and the catecholamine norepinephrine will up-regulate 
the expression of MUel in vitro, our results indicate that the glucocorticoid alone up-
regulated the expression of MUel, whereas the norepinephrine alone did not influence 
the expression ofMUCl. 
Our finding that physiologically relevant concentration of cortisol, found at the level 
of the tumor of stressed individuals, enhances the tumor antigen MUCI expression in 
DU-145 prostate cancer cells adds to the knowledge of existing mechanisms by which 
psychological stress may affect tumor progression. Thus, since it is well known that the 
abundant expression of MUC 1 correlates with metastasis (Papadimitriou et aL 1999) data 
presented in this thesis may provide a suggestive link betWeen high levels of 
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psychological stress and poorer prognosis in prostate cancer patients. However~ in order 
to conclude that chronic psychological stress may influence tumor progression in cancer 
patient populations, further studies must be designed as the definitive answer to this 




As already discussed, there is growing experimental and clinical evidence suggesting 
that chronic psychological stress is associated with cancer growth and progression 
(Thaker et aL 2006, Yang et al. 2006; Sood et al. 2006; Landen et al. 2007; Lutgendorf et 
al. 2008). The purpose of this study was to investigate the biochemical and molecular 
effects of the stress honnones cortisol and norepinephrine on the expression of the tumor 
antigen MUCI. We hypothesized that the glucocorticoid cortisol and the catecholamine 
norepinephrine will up-regulate the expression of MUCI in DU-145 prostate cancer cell 
line. 
Prior to establishing robust experimental conditions, initial experiments were designed 
at selecting the most suitable hormone responsive cancer cell line, stress hormones 
concentrations, and exposure times. See Figures 9-12. Data arising from initial 
experiments show the difference in MUC 1 expression across different breast cancer cell 
lines. The estrogen-dependent nature of some breast cancer cell lines as well as the lack 
of cross-talk with the MUCI receptor could explain whywe did not see an up-regulation 
of cortisol on MUCI expression (Lippman et al. 1976). For example, 3 and 15 days 
treatment with cortisol decreased MUCI expression in MCF7 cells. Since it is known 
(Lippman et al. 1976) that the interaction of estrogen with specific cytoplasmic receptor 
molecules is the first step in the pathway through which steroid hormones regulate 
phenotypic expression in breast cancer cells, the lack of estrogen in the tissue culture 
media can explain the down-regulation of MUCI expression in MCF7 cells. In addition, 
Lippman et al. (1976) reported that treatment with dexamethasone"'~l 0-7 M has inhibitory 
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effect on MCF7 cells and that cortisol inhibits DNA synthesis in MCF7 cells. In contrast, 
norepinephrine alone had a small effect of MUe 1 expression in MCF7 and MDA~MB-
453 cells after treating them for 2, 3, or 10 days. See Figures 9B and 11. Since 
norepinephrine binds to the J3- adrenergic receptor and both of these cell lines expresses 
this receptor, a small effect on Muel expression in MCF7 and MDA-MB-453 cells was 
seen. After collecting preliminary data on treating different cancer cell lines with different 
concentrations of the stress hOffilones and varying exposure times, we decided to choose 
DU-14S the prostate cancer cell line as an experimental model to test our hypothesis and 
treat cells with 10-7 M of both stress hormones for 3, 6, or 10 days. In addition, the 
decision to expose cancer cells to stress honnones during these specific time points was 
based on previously published study showing MUCI up-regulation by synthetic 
glucocorticoid in DU-14S prostate cancer cells using similar exposure times (Imai et aL 
2004). 
The key finding of this study is the identification of the glucocorticoid pathway which 
mediated the up-regulation of Mue 1 in DU-145 prostate cancer cells. More specifically, 
~'. 
data derived from experiments indicate that physiologically relevant concentrations of the 
glucocorticoid cortisol found at the site of the tumor in patients under chronic 
psychological stress (10-7 M) (Sloan et al. 2010; Shimizu et aL 1994; Madden et al. 1995) 
up-regulates tumor antigen MUe1 under protein and mRNA levels in DU-145 prostate 
cancer cell line. The protein levels of MUCI antigen were assayed by cell based ELISA 
and flow cytometry. The latter technique yielded a higher expression of MUCI than 
ELISA. This could be explained by the fact than in flow cytometry the detection of 
Muel is determined while the protein is in suspension, whereas in ELISA the protein is 
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bound to the plate. Therefore, if washing away nonspecifically bound materials fails, the 
detection of specific protein may become inaccurate. In addition, to nonnalize MUCI 
protein levels to the total cellular protein level, the Bradford Colorimetric Assay was used 
in combination with the ELISA assay. Data extracted from these assays show that cells 
treated with cortisol alone for 3-10 days up-regulated Muel expression by 
approximately 2-fold at each time point with the highest up-regulation (7-fold) observed 
in cells treated for 10 days as assayed by flow cytometry. See Figure 30. These findings 
are consistent with the literature (Imai et a1. 2004) which documents MUCI up-regulation 
with synthetic glucocorticoid dexamethasone (10-8 M). Norepinephrine alone did not 
influence MUCI expression at any time point in any of the experiments. The migration 
assay revealed that treating DU .. 145 cells with cortisol may increase the invasive 
potential of prostate cancer cells.. Stress honnone mediated invasion was observed by 
other researchers as well (Sood et aL 2006). Specifically, this study demonstrated that 
norepinephrine, epinephrine, and cortisol enhanced the invasive potential of certain 
ovarian cancer cells. 
In addition to the observed increased in protein le<'els of MUCl, we also saw an 
increase in MUCI mRNA levels after treating cells with cortisoL More specifically., 
treating DU-145 cells for 6 or 10 days, we observed a 6 and 4 -fold increase in mRNA 
levels. Since we saw an increase in protein levels of MUC 1 during these exposure times, 
we also expected to see an increase of the mRNA levels. However., our data revealed that 
3 day treatment did not increase the levels of mRNA in DU-145 cells, but resulted in the 
increase of the amount of a protein being produced as measured by ELISA and flow 
"-. 
cytometry. No changes of mRNA concurrent with up-regulation of protein expression 
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may occur when a protein half-life is increased due to stabilization or by the increased 
translation. 
Unexpectedly, although consistent throughout all the experiments, norepinephrine 
alone did not have any effect on MUCI expression in DU-145 prostate cancer cells. As 
was discussed in the literature review., it has been suggested that norepinephrine can 
promote various steps essential for tumor metastasis; including invasion and migration, 
through activation of the tumor cell cyclic AMP protein kinase signaling pathway by the 
~-adrenergic receptor (Thaker et al. 2006, Yang et al. 2006; Sood et at 2006; Landen et 
al. 2007; Lutgendorf et al. 2008). Since the current study has focused on the 
glucocorticoid receptor, it is plausible to assume that the lack of norepinephrine effect 
was due to the experimental design of the study which did not include any assessments of 
the p-adrenergic receptor. Furthennore, it has been documented (Shi et al. 2007) that 
most of the adrenergic receptor in DU-145 cells is localized in intracellular compartments 
in a nonfunctional state. Assuming that norepinephrine acts via andrenergic receptor 
pathway, these findings may explain why norepinephrine alone did not alter the 
expression ofMUCl in DU-145 prostate cancer cells. '/ 
Findings of this study should be viewed in "light of certain considerations and 
limitations. First, from the data presented above, it is unclear whether the detected 
enhancement of MUC 1 expression is due to the glucocorticoid receptor. In order to 
address this possibility, future research should include the use of the glucocorticoid 
receptor antagonist - RU 38486 and detennine whether the stress hormones effect on 
MUCI could be blocked by the use ofRU 38486. 
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Second, cortisol, as it was mentioned in the introduction, does· not function in 
isolation. It is just one of several chemical mediators of the stress response. 
Catecholamines, cytokines, and other glucocorticoids are just a few of the physiological 
mediators that may work in a synergistic manner along with cortisol and future studies 
using a more complex combination of these mediators may contribute to a more 
comprehensive understanding of the psychological stress effects on tumor progression. 
Third, although the data suggest that DU-I45 cells treated with cortisol for 6 and 10 
days increased the mRNA levels, the nature of this increase is unknown. Future 
experiments should investigate whether this increase is due to increased transcription or 
increased mRNA stability. 
Finally, an in vitro model system just artificially mimics the stress response. It is 
extremely limited and cannot reproduce what happens at the cellular and molecular level 
in the body where there are complex arrays of mediators which may have a hugely 
different effect on stress hormone induced MUCl expression, to that seen in in vitro 
systems. However, as of today, this work offers the only direct biochemicallink between 
the mediators of psychological stress and Muel expression in prostate cancer cells. 
Further research could be done in a number of ways, including the investigation of 
additional mechanisms of MUCI up-regulation by stress honnones, and by targeting 
MUC 1 for immunotherapy with two potential therapeutic approaches: monoclonal 
antibody therapy and cytotoxic T cell killing therapy. The first approach would include 
targeting over-expressed MUe 1 with HMFG 1 IgG hence inducing NK cell and Cytotoxic 
T cell killing by antibody-dependent cell-mediated cytotoxicity. The second approach 
"'., 
would include activation of autologous T cells using peptide'S from the MUCI core 
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protein resulting in antigen processing and co-expression with MHC Class II and re -
infusion of cells back into the patient. Also, additional research should include studies 
designed to look at the psychological stress effect on the initiation of the cancer, not only 
at the progression of the tumor. 
Although our understanding of the bio-behavioral influences on cancer pathogenesis is 
expanding, however, the molecular pathways mediating this effect have not been 
completely delineated. Since, to the best of our knowledge, there are no studies 
conducted investigating the effect of the stress honnone cortisol on the expression of 
MUC 1, therefore, the results of this study greatly contribute to our understanding of how 
physiologically relevant concentration (10.7 M) of the stress honnone cortisol found at the 





Cancer diagnosis and treatment can lead to dysregulation of psychological and 
biological processes. The activation of the pituitary adrenal axis leading to increased 
levels of cortisol have been associated with adverse psychological effects such as 
emotional distress, major depressive disorder, panic disorder, and bipolar mania 
(Luecken & Compas, 2002). Research shows that psychological stress still remains a 
significant problem for cancer patients, their family members, and care givers (Adler & 
Page, 2008; Abrahamson et a1. 2011). A greater level of stress is found to be associated 
with a greater severity of the disease (Schag et al. 1993). According to some researchers 
(Abrahamson et a1. 2011; Jacobsen 2010), nearly 35-45% of cancer patients in the United 
States report significant stress. Furthermore, it has been suggested (Abrahamson et a1. 
2011; Abrahamson 2010) that this number is most likely an underestimation. Also, 
psychological stress is not only being under diagnosed., but is also poorly managed by the 
United States health system (Abrahamson et a1. 2011; Jacobsen 2010). Although the 
National Comprehensive Cancer Network recommends' routine screening for distress 
upon admission and the critical points in the disease process, these guidelines are not 
consistently implemented in hospitals. This that being said, this study highlights the 
necessity to pay more attention to the psychosocial needs of cancer patients not only due 
to the unmet patients' psychosocial needs, but also due to the possible effect that chronic 
stress may have on tumor progression. 
Stress hormones have been shown not only able to influence tumor progression, but 
also may lead to chemoresistance of certain agents. For example., Flint et al. (2009) 
48 
reported that cortisoL, norepinephrine and epinephrine induced drug resistance to a widely 
used chemotherapeutic agent., paclitaxel in MDA-MB-231 cells. These findings 
emphasize the translational value of the stress hormones in cancer care. 
Furthennore, the data generated from this thesis not only identify specific proteins., 
such as MUC 1, and a glucocorticoid pathway that may link psychological stress to tumor 
progression, but it also indicates that targeting the neuroendocrine system may be a way 
forward in the development of new strategies for reducing psychological stress among 
cancer patients. If more in depth studies confirm that the increase in the tumor marker, 
MUCl, is caused by elevated levels of stress hormones, antibodies, such as the 
huHMFG 1, used for this thesis work, could be administered to patients in the clinic in an 
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FIGURE 5. Core Protein of MUCI. The Amino Acids in Bold Refer to Potential O-linked 
Glycosylation Sites. 
Adoptedfrom J. Tay/or-Papadimitriou et al. / Biochimica et Biophysica Acta 1455 (1999) 301-313. 
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FIGURE 8. Alteration of cell growth in DU-145 cells by CORT and NE (0.1 11M). DU-145 cells were 
seeded at 2 x 104 cells/ml in separate tissue culture dishes. This time point was considered day O. Growth 
studies were performed in triplicate, where three separate measurements were obtained per day. Growth 
was determined by cell counts on days 0, 1, 2 and.4, by using a Beckman Coulter counter. Results denote 
the average of the three separate experiments. Significant increase was observed after 4 days compared to 
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FIGURE 9. (A, B, C). MUCI 
expression in MCF7 cells treated 
with CORT & NE for 2, 3, or 15 
days. 
p < 0.05 compared to controls; error bars represent standard error 
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FIGURE 10. (A, B, C). MUCI expression 
in MDA-MB-231 breast cancer cells 
treated with CORT for 3, 8, or 11 days. 
p < 0.05 compared to controls; error bars represent standard error 
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FIGURE 11. (A, B). MUCI expression in 
MDA-MB-453 breast cancer cells treated 
with NE (0.1 ~M) for 2 or 10 days. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean 
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FIGURE 12. (A, B). MUCI expression in 
MDA-MB-231 & DU-145 cancer cells 
treated with stress hormones (0.1 f.1M) for 
3 or 58 days. 
* p < 0.05 compared to controls; error bars represent standard error of the 
mean; data generated from two independent experiments. 
ELISA: 3 Day without ceO # 
1.6 












CO ITROL CORT NE CORT &NE 
ELISA: 3 Days ,vith ceO # adju tmeot 
1.5 
























.....) 0. 1 
o 
CO:N"TROL CORT NE CORT& 
NE 
ELISA: 6 Days ,vithout cell # adjustmeot 
CONTROL CORT NE CORT&NE 
ELISA: 6 Days with cell # adjustmeot 
COr ;TROL CORT CORT &NE 
62 
FIGURE 13. MUCI expression in DU-145 cells 
treated for 3 days with stress hormones (0.1 
JiM). Data generated from 2 independent 
experiments. Results presented without & with cell 
number adjustment. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean 
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FIGURE 14. MUCI expression in DU-145 cells 
treated for 6 days with stress hormones (0.1 
JiM). Data generated from 2 independent 
experiments. Results presented without & with 
cell number adjustment. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean 
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FIGURE 15. MUCI expression in DU-145 
cells treated for 10 days with stress hormones 
(0.1 llM). Data generated from 2 independent 
experiments. Results presented without & with 
cell number adjustment. 
* p < 0.05 compared to controls; error bars represent standard error of the mean; 
data generated from two independent experiments. 
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FIGURE 16. Flow Cytometric Analysis 
of MUCI expression in DU-145 cells 
after treatment for 3 days with stress 
hormones (0.1 IlM). Data generated 
from two independent experiments. 
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FIGURE 17. Flow Cytometric Analysis 
of MUCI expression in DU-145 cells 
after treatment for 6 days with stress 
hormones (0.1 IlM). Data generated from 
two independent experiments. 
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FIGURE 18. Flow Cytometric Analysis 
of MUCI expression in DU-145 cells 
afte.r treatment for 10 days with stress 
hormones (0.1 IlM). Data generated from 
two independent experiments. 
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FIGURE 19. Flow Cytometric 
Analysis of MUC1 expression in DU-
145 cells after treatment for 3 - 10 
days with stress hormones (0.1 11M). 
Data generated from two independent 
experiments. 
*p < 0.05 compared to controls; error bars represent standard error 
of the mean. 
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FIGURE 23. Matrigel Invasion Assay. 
DU-145 cells pre-treated with CORT, NE, 
& BOTH (0.1 IlM) for 3 days. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean. 
Fold Expression: 
CONTROL-1 
CORT - 1.4 fold 
NE - 0.9 fold 
CORT & NE - 1.6 fold 
FIGURE 24. Matrigel Invasion Assay. 
DU-145 cells pre-treated with CORT, NE, 
& BOTH (0.1 IlM) for 6 days. 
*p < 0.05 compared to controls; error bars represent standard error 
of the mean. 
Fold Expression: 
CONTROL -1 
CORT - 1.4 fold 
NE - 0.9 fold 
CORT & NE - 3.2 fold 
FIGURE 25. Matrigel Invasion Assay. 
DU-145 cells pre-treated with CORT, NE, 
&BOTH (0.1 IlM) for 10 days. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean. 
Fold Expression: 
CONTROL - 1 
CORT - 1.6 fold 
NE - 1.1 fold 
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FIGURE 26. RT-PCR: DU-145 cells 
treated with CORT, NE, & BOTH 
(0.1 J.1M) for 3 days. Results are 
generated from two independent 
experiments. 
p < 0.05 compared to controls; error bars represent standard error 
of the mean 
Fold Expression: 
CONTROL -1 
CORT - 1.2 fold 
NE - 0.5 fold 
CORT & NE - 0.9 fold 
FIGURE 27. RT-PCR: DU-145 cells 
treated with CORT, NE, & BOTH 
(0.1 J.1M) for 6 days. Combined 
results of three independent 
experiments . 
• p < 0.05 compared to controls; error bars represent standard 
error of the mean. 
Fold Expression: 
CONTROL-1 
CORT - 6 fold 
NE - 2 fo1d 
CORT & NE - 3.6 fold 
FIGURE 28. RT-PCR: DU-145 cells 
treated with CORT, NE, & BOTH 
(0.1 J.1M) for 10 days. Results are 
generated from three independent 
experiments. 
. p < 0.05 compared to controls; error bars represent standard 
error of the mean. 
Fold Expression: 
CONTROL - 1 
CORT - 3.5 fold 
NE - 1 fold 
CORT & NE - 1.3 fold 
MUCI Expres ion by RT -PCR: 3, 6 10 Days 
* 
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CORT 11.43 1.72 1.58 2.22 2.06 
NE 1.03 1.14 1.08 1.22 
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FIGURE 29. RT-PCR: DU-145 cells 
treated with CORT, NE, & BOTH 
(0.1 J.1M) for 3, 6, or 10 days. Results 
are expressed in normalized fold 
expression compared to the house 
keeping gene - GAPDH. 
*p < 0.05 compared to controls; error bars represent standard 
error of the mean. 
Normalized per RT-PCR 
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FIGURE 31. Summary of Chronic Psychological Stress Effect ofMUCl Expression in DU-145 
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